Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference
Andrew A. House(Western University), Peter A. McCullough(Parkland Foundation), G. Sheinfeld(University of Maryland, College Park), Ilona Bobek, Sachin Soni(MaxCure Hospitals), Andrew Shaw(Abiomed (United States)), Piotr Ponikowski(Wroclaw Medical University), Nadia Aspromonte(Agostino Gemelli University Polyclinic), Mikko Haapio(Helsinki University Hospital), Tomás Berl(University of Colorado Anschutz Medical Campus), Giorgio Vescovo(Ospedale San Bortolo), Sunil Mankad(Mayo Clinic in Arizona), D. Cruz(Ospedale San Bortolo), Hans L. Hillege(University Medical Center Groningen), Sean M. Bagshaw(Alberta Health Services), Alberto Palazzuoli, Alan S. Maisel(San Francisco VA Medical Center), Luciano Daliento(University of Padua), Nereo Zamperetti(Ospedale San Bortolo), Claudio Ronco(Ospedale San Bortolo), S. D. Anker(Charité - Universitätsmedizin Berlin), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), P. Zanco(Ospedale San Bortolo), Abigail Davenport(UCL Australia), Federico Ronco(University of Padua), R. Bellomo(The University of Melbourne), Inder S. Anand(University of Minnesota), N. Katz(George Washington University)
Cited by 146
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
|Circulation|2003|3.8k